secwatch.observer — SEC 8-K summary
======================================

Issuer:     SAB Biotherapeutics, Inc. (SABS)
CIK:        0001833214
Form:       8-K
Filed at:   2023-02-07T23:59:59+00:00
Accession:  0001437749-23-002624
Event type: other_material
Sentiment:  neutral
Materiality: 0.25
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SAB Biotherapeutics presents DiversitAb platform and clinical data at BIO CEO Conference
--------------------------------------------------------------------------------

- Presentation highlighted DiversitAb platform and completed trial data showing polyclonal antibody efficacy against mutating pathogens.
- No specific financial results or forward guidance were disclosed in the 8-K or presentation summary.
- Audio recording and presentation slides made available on Company's IR website prior to conference.
- Information furnished under Item 7.01 and not deemed filed for SEC liability purposes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1833214/000143774923002624/0001437749-23-002624-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1833214/000143774923002624/sabs20230206_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-002624

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer